חוב כולל להון: Cardiff Oncology Corp (CRDF)

The market price visualization of the total debt-to-equity ratio for Cardiff Oncology, Inc. (CRDF) stands at 0.02. The business automates the creation of inhibitors using AI and robotics to eliminate human error. Cardiff Oncology, Inc. (CRDF) develops molecules that overcome tumor resistance to restore the efficacy of chemotherapy. Development relies on a network of medical centers with high patient retention, where FDA regulatory decisions remain the key risk.

Total debt-to-equity measures the proportion of borrowed funds relative to shareholders' equity, determining the degree of financial leverage. This ratio helps investors assess bankruptcy risks and the extent of the business's dependence on creditors. Current price action regarding asset leverage has recorded a value of 0.02. For Cardiff Oncology, Inc. (CRDF), such a balance sheet structure is supported by the protected status of targeted drug development. The humanitarian nature of the industry minimizes external sanction risks, thereby stabilizing the debt load.